

IQVIA RDS Italy S.r.l.
Sede Legale e Operativa
Via F. Filzi 29
20124 Milano

[iqvia.com](https://www.iqvia.com)

Alla c.a. della
IRCCS - ISMETT
Via Tricomi 5,
90127, Palermo

SUBJECT: Site recruitment activity during 2025

Study title: A Phase 3 open-label extension (OLE) study to evaluate the long-term safety and efficacy of ralinepag in subjects with World Health Organization (WHO) Group 1 pulmonary arterial hypertension (PAH) (ADVANCE Extension)

Protocol Code: APD811-303

EudraCT Number: 2023-509305-68-00
(hereinafter referred to as “Study”)

Hereby, IQVIA on behalf of Sponsor United Therapeutics as CRO of the trial in object, declares that the recruitment activity carried out by the IRCCS ISMETT, Palermo has enrolled in total N° 2 patients, in particular N° 2 in 2025.

This declaration is released under IRCCS’s request to comply with the requirements of the Ministry of Health regarding the evaluation of the activities carried out by the IRCCS - Reporting Current Research 2026 (activities carried out in 2025).

In Faith,

Fabrizio Forini

Senior Director, Clinical Operations and Site Management Head Italy IQVIA

Signed by Fabrizio Forini
 | I have reviewed this document
24-Mar-2026 | 9:20:25 AM PDT
675210C55637444993ADB3892149AE9C